- HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER
-
The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof,.Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers via inhibition of MAT2B, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted.
- -
-
Paragraph 00943; 00944
(2019/10/19)
-
- IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AS LSD-1 INHIBITORS
-
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. Th
- -
-
Paragraph 0213; 0214
(2019/12/04)
-
- ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
-
A compound comprising a ligand LA coordinated to a metal M wherein ring A, ring T, and ring W are independently selected from a 5-membered or 6-membered heterocyclic or carbocyclic ring, and the ring W is fused to the ring T. The metal compound
- -
-
Paragraph 0158; 0159
(2020/01/12)
-
- PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS
-
The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
- -
-
Paragraph 0229; 0230; 0231
(2018/12/13)
-
- FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES
-
The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.
- -
-
Page/Page column 185-186
(2013/03/26)
-